In addition to ibrutinib, clients with M-CLL, devoid of TP53 aberrations and in good shape adequate to tolerate FCR therapy, may still be superior candidates for that latter, Using the profit being this cure might be done in 6 months whilst ibrutinib needs to be taken indefinitely. This option can be particularly important for non-compliant clients